Literature DB >> 26024289

Inhibitors of alanine racemase enzyme: a review.

Mohammed Afzal Azam1, Unni Jayaram1.   

Abstract

Alanine racemase is a fold type III PLP-dependent amino acid racemase enzyme catalysing the conversion of l-alanine to d-alanine utilised by bacterial cell wall for peptidoglycan synthesis. As there are no known homologs in humans, it is considered as an excellent antibacterial drug target. The standard inhibitors of this enzyme include O-carbamyl-d-serine, d-cycloserine, chlorovinyl glycine, alaphosphin, etc. d-Cycloserine is indicated for pulmonary and extra pulmonary tuberculosis but therapeutic use of drug is limited due to its severe toxic effects. Toxic effects due to off-target affinities of cycloserine and other substrate analogs have prompted new research efforts to identify alanine racemase inhibitors that are not substrate analogs. In this review, an updated status of known inhibitors of alanine racemase enzyme has been provided which will serve as a rich source of structural information and will be helpful in generating selective and potent inhibitor of alanine racemase.

Entities:  

Keywords:  Alanine racemase; antibacterial activity; cycloserine; d-alanine; pyridoxal 5′-phosphate

Mesh:

Substances:

Year:  2015        PMID: 26024289     DOI: 10.3109/14756366.2015.1050010

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  13 in total

Review 1.  Small Molecule Sensors Targeting the Bacterial Cell Wall.

Authors:  Matthew F L Parker; Robert R Flavell; Justin M Luu; Oren S Rosenberg; Michael A Ohliger; David M Wilson
Journal:  ACS Infect Dis       Date:  2020-06-09       Impact factor: 5.084

2.  Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.

Authors:  Maxwell T Chirehwa; Richard Court; Mariana de Kock; Lubbe Wiesner; Nihal de Vries; Joseph Harding; Tawanda Gumbo; Gary Maartens; Rob Warren; Paolo Denti; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 3.  Amino Acid Based Antimicrobial Agents - Synthesis and Properties.

Authors:  Michał G Nowak; Andrzej S Skwarecki; Maria J Milewska
Journal:  ChemMedChem       Date:  2021-10-01       Impact factor: 3.540

4.  Selection and characterization of alanine racemase inhibitors against Aeromonas hydrophila.

Authors:  Yaping Wang; Chao Yang; Wen Xue; Ting Zhang; Xipei Liu; Jiansong Ju; Baohua Zhao; Dong Liu
Journal:  BMC Microbiol       Date:  2017-05-25       Impact factor: 3.605

5.  Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.

Authors:  Wael A Alghamdi; Abdullah Alsultan; Mohammad H Al-Shaer; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Ketevan Barbakadze; Eric Houpt; Maia Kipiani; Lali Mikiashvili; Stephan Schmidt; Scott K Heysell; Russell R Kempker; J Peter Cegielski; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 6.  Strategies to Overcome Antimicrobial Resistance (AMR) Making Use of Non-Essential Target Inhibitors: A Review.

Authors:  Giannamaria Annunziato
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

Review 7.  Cell Surface Biosynthesis and Remodeling Pathways in Mycobacteria Reveal New Drug Targets.

Authors:  Moagi Shaku; Christopher Ealand; Bavesh D Kana
Journal:  Front Cell Infect Microbiol       Date:  2020-11-12       Impact factor: 5.293

Review 8.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

9.  Inhibition of O-acetylserine sulfhydrylase by fluoroalanine derivatives.

Authors:  Nina Franko; Konstantinos Grammatoglou; Barbara Campanini; Gabriele Costantino; Aigars Jirgensons; Andrea Mozzarelli
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

10.  C-Terminal 1-Aminoethyltetrazole-Containing Oligopeptides as Novel Alanine Racemase Inhibitors.

Authors:  Laszlo A Kondacs; Sylvain Orenga; Rosaleen J Anderson; Emma C L Marrs; John D Perry; Mark Gray
Journal:  Molecules       Date:  2020-03-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.